These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 3479250

  • 41. [Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C].
    Kamiya K, Uchida M, Ueda T, Nakamura T.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul 20; 25(7):1419-27. PubMed ID: 2212834
    [Abstract] [Full Text] [Related]

  • 42. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
    Gandhi V, Du M, Kantarjian HM, Plunkett W.
    Leukemia; 1994 Sep 20; 8(9):1463-8. PubMed ID: 8090026
    [Abstract] [Full Text] [Related]

  • 43. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Biochem Pharmacol; 2009 Jun 15; 77(12):1780-6. PubMed ID: 19428333
    [Abstract] [Full Text] [Related]

  • 44. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.
    Donehower RC, Karp JE, Burke PJ.
    Cancer Treat Rep; 1986 Sep 15; 70(9):1059-65. PubMed ID: 3461882
    [Abstract] [Full Text] [Related]

  • 45. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS.
    Clin Cancer Res; 2005 Dec 01; 11(23):8403-12. PubMed ID: 16322302
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 01; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
    Colly LP, Peters WG, Willemze R.
    Cancer Res; 1986 Aug 01; 46(8):3825-7. PubMed ID: 3460691
    [Abstract] [Full Text] [Related]

  • 51. [Is the pharmacokinetic profile of cytarabine clinically relevant?].
    Boos J.
    Klin Padiatr; 1992 Aug 01; 204(4):198-203. PubMed ID: 1518256
    [Abstract] [Full Text] [Related]

  • 52. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
    Grant S, Baker M, Bhalla K.
    Leukemia; 1993 Dec 01; 7(12):1933-8. PubMed ID: 8255091
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S, Goto N, Nakamura T, Ueda T.
    Cancer Res; 1999 Jun 01; 59(11):2629-34. PubMed ID: 10363985
    [Abstract] [Full Text] [Related]

  • 55. A critical role for uridine nucleotides in the regulation of deoxycytidine kinase and the concentration dependence of 1-beta-D-arabinofuranosylcytosine phosphorylation in human leukemia cells.
    White JC, Capizzi RL.
    Cancer Res; 1991 May 15; 51(10):2559-65. PubMed ID: 2021937
    [Abstract] [Full Text] [Related]

  • 56. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.
    Gandhi V, Plunkett W.
    Cancer Res; 1988 Jan 15; 48(2):329-34. PubMed ID: 3335008
    [Abstract] [Full Text] [Related]

  • 57. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, Johno I, Akiyama Y.
    Cancer Res; 1983 Jul 15; 43(7):3412-6. PubMed ID: 6850647
    [Abstract] [Full Text] [Related]

  • 58. A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia.
    Stone RM, Spriggs DR, Dhawan RK, Arthur KA, Mayer RJ, Kufe DW.
    Leukemia; 1990 Dec 15; 4(12):843-7. PubMed ID: 2243507
    [Abstract] [Full Text] [Related]

  • 59. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO, Paul CY, Gahrton CG, Peterson CO.
    Cancer Res; 1985 May 15; 45(5):2373-5. PubMed ID: 3986778
    [Abstract] [Full Text] [Related]

  • 60. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
    Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W.
    Leukemia; 1990 Feb 15; 4(2):95-9. PubMed ID: 2304361
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.